Advice
following an abbreviated submission:
travoprost (Travatan®) is accepted for use within NHS Scotland.
Indication under review: decrease of elevated intraocular pressure in paediatric patients aged 2 months to <18 years with ocular hypertension or paediatric glaucoma.
In a randomised, double-masked study of paediatric patients with glaucoma or ocular hypertension, travoprost was demonstrated to be non-inferior to a beta blocker eye drop preparation in terms of mean reduction in intra-ocular pressure.
Another topical ocular prostaglandin analogue preparation is licensed for use in children for this indication and is considerably cheaper. In reducing intra-ocular pressure, travoprost is comparable in effect to other drugs in its class.
Download detailed advice111KB (PDF)
Medicine details
- Medicine name:
- travoprost (Travatan)
- SMC ID:
- 1091/15
- Indication:
- decrease of elevated intraocular pressure in paediatric patients aged 2 months to <18 years with ocular hypertension or paediatric glaucoma.
- Pharmaceutical company
- Alcon Laboratories UK Ltd
- BNF chapter
- Eye
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 October 2015